Forxiga Tablets Specific Clinical Experience Investigation for Elderly
NCT ID: NCT02200627
Last Updated: 2017-02-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1724 participants
OBSERVATIONAL
2014-09-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Development of ADRs specified as Key Investigation Items and the risk factors
* Contributing factors possibly having an impact on the safety and efficacy
* Development of ADRs unexpected from the Precautions for use and ADRs under actual drug use
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use
NCT02200666
Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects
NCT04473417
Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
NCT02367131
To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes
NCT01176097
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
NCT00856908
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
In addition, patients receiving the study drug of Forxiga before the launch should be included also.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Aichi, , Japan
Research Site
Akita, , Japan
Research Site
Aomori, , Japan
Research Site
Chiba, , Japan
Research Site
Ehime, , Japan
Research Site
Fukui, , Japan
Research Site
Fukuoka, , Japan
Research Site
Fukushima, , Japan
Research Site
Gifu, , Japan
Research Site
Gunma, , Japan
Research Site
Hiroshima, , Japan
Research Site
Hokkaido, , Japan
Research Site
Hyōgo, , Japan
Research Site
Ibaraki, , Japan
Research Site
Ishikawa, , Japan
Research Site
Kagawa, , Japan
Research Site
Kagoshima, , Japan
Research Site
Kanagawa, , Japan
Research Site
Kochi, , Japan
Research Site
Kumamoto, , Japan
Research Site
Kyoto, , Japan
Research Site
Mie, , Japan
Research Site
Miyagi, , Japan
Research Site
Miyazaki, , Japan
Research Site
Nagano, , Japan
Research Site
Nagasaki, , Japan
Research Site
Nara, , Japan
Research Site
Niigata, , Japan
Research Site
Numakunai, , Japan
Research Site
Okayama, , Japan
Research Site
Osaka, , Japan
Research Site
Ōita, , Japan
Research Site
Saga, , Japan
Research Site
Saitama, , Japan
Research Site
Shiga, , Japan
Research Site
Shimane, , Japan
Research Site
Shizuoka, , Japan
Research Site
Tochigi, , Japan
Research Site
Tokushima, , Japan
Research Site
Tokyo, , Japan
Research Site
Tottori, , Japan
Research Site
Toyama, , Japan
Research Site
Wakayama, , Japan
Research Site
Yamagata, , Japan
Research Site
Yamaguchi, , Japan
Research Site
Yamanashi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1692C00015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.